Drug Discovery

ENA Respiratory partners with COPD Foundation for antiviral nasal spray

ENA Respiratory has collaborated with not-for-profit organisation COPD Foundation for the development of INNA-051, a pan-antiviral nasal spray, for chronic lung diseases patients.

Synthego raises $200m to accelerate discoveries of new therapeutics

Genome engineering firm Synthego has raised $200m in Series E funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research.

Adcentrx Therapeutics, AvantGen form partnership for discovery of antibodies

Biotechnology firm Adcentrx Therapeutics and AvantGen have formed a three-year, multi-target partnership for the discovery of antibodies to be developed into new  antibody drug conjugate (ADC) therapeutic candidates.

Nurosene, Cyclica partner for neurodegenerative disease drug development

Nurosene Health, through its subsidiary NetraMark, has collaborated with Cyclica for the development of new drugs to treat neurodegenerative diseases.

Seismic raises $101m to advance two drug programmes to clinic

Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.

Healx secures option to license rights from Ovid to develop gaboxadol

Healx, an AI-powered, technology company involved in the next generation of drug discovery, has secured an exclusive option to license rights to develop and commercialize gaboxadol from biopharmaceutical company Ovid Therapeutics.

NHS to roll out new drug to treat advanced womb cancer

The National Health Service (NHS) in England has announced that Dostarlimab, a drug to treat advanced womb cancer, will be rolled out for women in the country.

Mersana, Janssen Biotech partner to discover new ADC product candidates

Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research collaboration and license agreement for the discovery of new antibody-drug conjugates (ADCs) for three targets.

Alvotech, BiosanaPharma partner to develop biosimilar for Xolair

Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).